Ganirelix
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Ganirelix: From Undetermined Original Indication to Hypertrichosis
One-Sentence Summary
Ganirelix (DrugBank DB06785) is a GnRH (gonadotropin-releasing hormone) antagonist; its original approved indication is not captured in this evidence pack, and its detailed mechanism of action is also flagged as a data gap. The TxGNN model’s top prediction is Hypertrichosis (disease), with a very high similarity score but zero clinical trials and zero literature currently supporting this specific link.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no licenses or indication records on file in this data pack |
| Predicted New Indication | Hypertrichosis (disease) |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| US Market Status | ✗ Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack (flagged as data gap DG002). Based on the mechanistic-link notes the model itself generated across this drug’s candidate list, ganirelix is consistently described as a GnRH antagonist that suppresses pituitary LH/FSH secretion — this is the drug’s known pharmacological class, even though a formal MOA record was not retrieved here.
For the top-ranked candidate, hypertrichosis (excess hair growth), the system’s own rationale explicitly states there is no known mechanistic connection between GnRH/LH-FSH suppression and hair-follicle growth regulation, and that the prediction carries no supporting clinical or literature data. In other words, the high TxGNN similarity score reflects a graph-embedding pattern, not a validated pharmacological hypothesis.
It’s also worth noting that rank 3 in this same batch (“malformation syndrome with odontal/periodontal component”) returned 20 literature hits, but manual review found all 20 to be generic periodontology papers with no mention of ganirelix or GnRH pathways — a likely keyword/embedding false-positive. This is a signal that this batch of predictions, as a whole, needs cautious interpretation rather than face-value trust in high similarity scores.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
No marketing authorization (NDA/license) records are available in this data pack — market_status is recorded as “未上市” (not marketed) with 0 total licenses on file.
Safety Considerations
Please refer to the package insert for safety information. (Key warnings, contraindications, and drug interaction data were all queried but not found in this data pack — DG001, TFDA label warnings, is flagged as a Blocking-severity gap.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked candidate indication (hypertrichosis) has no clinical trials, no literature, and no plausible mechanistic link per the model’s own assessment — this is a pure L5 model-prediction-only signal at decision stage S0. Combined with two unresolved drug-level data gaps (missing regulatory safety label and missing MOA), this candidate cannot advance past initial screening.
To proceed, the following is needed:
- TFDA/FDA package insert (warnings, contraindications) — currently Blocking (DG001)
- Confirmed mechanism of action from DrugBank API — currently High severity (DG002)
- Original approved indication and regulatory license records for ganirelix, which are entirely absent from this pack
- Independent expert review of whether any GnRH-antagonist-to-hypertrichosis mechanistic hypothesis is biologically plausible, since none is currently supported by data
- If further candidates from this batch are pursued (e.g., precocious puberty entries, which are at least endocrinologically adjacent to GnRH pathways), re-run evidence collection specifically for those, since the current top-ranked candidate is not the most mechanistically coherent option in the list
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.